Barberry

Barberry (Berberis vulgaris L.)

1. Identity: Botanical Classification, Chemistry, and Common Forms

Botanical Identity

The genus Berberis, with more than 500 species, belongs to the family Berberidaceae. Berberis vulgaris, known as barberry or common/European barberry, is an evergreen shrub that possesses yellow, spiny, angled or sulcated bark, oblong, obovate, or elliptic leaves, yellow flowers, and red, oblong fruits. It grows in Asia and Europe and is a well-known herb in Iran. The plant grows abundantly across Iran, Turkey, the Caucasus region, and into Central Europe. Today, barberry also grows wild across North America, where it was introduced by European settlers. Iran remains one of the world's largest producers, particularly cultivating the seedless variety known as zereshk for culinary purposes.

Six known species of barberry include Berberis crataegina, Berberis integerrima, Berberis khorasanica, Berberis orthobotrys, Berberis vulgaris, and Berberis thunbergii var. atropurpurea. Among these, B. vulgaris is the most extensively studied for its medicinal properties. Related species such as B. aristata (tree turmeric), B. aquifolium (Oregon grape), and B. integerrima (purple-black barberry) share many of the same alkaloid constituents and appear in the scientific literature alongside B. vulgaris.

Chemically Active Parts

Berberine is the main active constituent and the most studied alkaloid. It is found throughout the plant, though it is more concentrated in the roots, bark, and stems. Berberine is present in the roots, rhizomes, stem, and bark of B. vulgaris and many other plants.

Common Preparations and Dosage Forms

Barberry is available in several preparations that have been used both traditionally and in modern research contexts:

• Dried fruit (zereshk): Widely used as a culinary ingredient in Iran and neighboring countries. Used in clinical trials at doses ranging from 3 g of barberry for 12 weeks in diabetic patients to 10 g/day of dried barberry in an 8-week randomized controlled trial.
• Barberry juice: 200 ml of barberry juice was used in one clinical trial examining effects on blood pressure, fasting blood sugar, and blood lipids in people with type 2 diabetes.
• Fruit extract capsules/tablets: 600 mg/day of barberry fruit extract was used for 6 weeks in one trial involving patients with metabolic syndrome.
• Isolated berberine: The purified alkaloid has been studied extensively in clinical trials, most commonly at 0.5 g three times daily (t.i.d.), and 300 mg three times daily in pharmacokinetic studies.
• Tincture: Tincture (1:5 in 60% ethanol) at 1–2 ml in water up to 3 times a day is a traditional preparation form.
• Decoction: A decoction is made by placing 1 teaspoon of dried material in one cup of cold water, bringing to the boil and simmering gently for 15–20 minutes, then straining; traditionally drunk 3 times a day.
• Root/bark powder: The powdered root or bark has historically been used in capsule and tablet form.

2. Key Constituents and Active Compounds

Alkaloids

The main isolated compounds from B. vulgaris are tannins, phenolic compounds, triterpenes (lupeol, oleanolic acid), sterols (stigmasterol, stigmasterol glucoside), and alkaloids (berberamine, palmatine, berberine, oxyberberine, columbamine, isocorydine, lambertinea, and magniflorine). Additionally, bisbenzylisoquinolines (oxycanthine), N-(p-trans-coumaroyl) tyramine, cannabisin G, and (±)-lyoniresinol have been isolated from this plant.

The key active constituents of barberry root and stem bark are isoquinoline alkaloids. Two classes have been identified: protoberberines (berberine, berbamine, jateorrhizine, and palmatine) and bisbenzylisoquinolines (oxycanthine).

In addition to alkaloids, organic acids such as chelidonic acid, citric acid, malic acid, resin, tannin, pectinic, and mucilagic substances are among the ingredients of barberry.

Polyphenols and Fruit Constituents

The fruit, leaves, roots, and bark of B. vulgaris contain a diverse array of bioactive compounds including alkaloids (e.g., berberine), anthocyanins (e.g., cyanidin-3-glucoside), phenolic acids (gallic acid, chlorogenic acid), and flavonoids. The anthocyanin content of the fruit—especially in purple-black varieties such as B. integerrima—contributes to its antioxidant and potential cardiovascular properties.

Berberine: Structure and Principal Identity

Berberine (BBR) is a plant quaternary ammonium salt from the group of isoquinoline alkaloids (2,3-methylenedioxy-9,10-dimethoxyprotoberberine chloride; C₂₀H₁₈NO₄⁺), with a molar mass of 336.36 g/mol. It can be isolated from a variety of plants, including Coptis chinensis (goldthread), Hydrastis canadensis (goldenseal), and Berberis aquifolium (Oregon grape), as well as from Berberis vulgaris. The presence of berberine is indicated by the yellow color in the inner stem bark, root bark, and root; the more yellow a tincture is, the more berberine it contains.

3. Traditional and Historical Use

Overview and Antiquity

Barberry (Berberis vulgaris L.), a member of the Berberidaceae family, has been widely utilized in traditional medicine for over 2,500 years and is increasingly recognized for its pharmacological properties. Barberry has had a long history in eastern and western medical tradition. In Iran and India, this history goes back to at least 3,000 years. Records of its medicinal use extend back to 650 BCE in Babylonia.

Ancient Egypt

In ancient Egypt, barberry fruit was used with fennel seeds to ward off pestilent fevers. This is among the oldest documented therapeutic uses of the plant and reflects an early recognition of its antimicrobial or antipyretic properties.

Traditional Iranian Medicine

Barberry is known for its anti-arrhythmic and sedative effects in Iranian traditional medicine. The traditional Iranian system of medicine understands barberry to have cold, dry energetics. It is traditionally used to check diarrhoea, strengthen the stomach, liver, and heart, eliminate excess bile, relieve thirst, and cool stomach heat and internal inflammations. According to traditional medicine, the fruit of this plant has a cold and dry nature. Ancient Egyptians used barberry and fennel seed to cure fever. Iranian physicians used it as a sedative, and it has been used to treat diarrhea by Indian physicians. This plant is still used in northern Europe to treat disorders of the bladder, liver, and gallbladder.

Ayurvedic and Indian Traditional Medicine

Indian Ayurvedic physicians used barberry in the treatment of dysentery. The species B. aristata has been used in traditional Chinese and Nepalese medicine and in the Ayurvedic medical system for many years. Decoctions of roots and stem barks from Indian Berberis species have been used as domestic treatment for conjunctivitis or other ophthalmic diseases, enlarged liver and spleen, hemorrhages, jaundice, and skin diseases such as ulcers. Decoctions of Indian barberry mixed with honey have also been reported for the treatment of jaundice and, combined with Emblic myrobalan, for urinary disorders such as painful urination.

Traditional Chinese Medicine

Berberine has long been used mainly as an agent against gastroenteritis, dysentery, and abdominal pain in traditional Chinese medicine contexts. The alkaloid berberine was historically included as an astringent in eye drops, though its use in this form has become rare.

European Folk Medicine

Barberry has played a prominent role in herbal medicine for more than 2,500 years. In European folk medicine it was used for nearly every gastrointestinal ailment, urinary tract, and respiratory infection. It has been used as a bitter tonic and antipyretic to support the liver and help remove cold from the body. In northern Europe, barberry was used to treat gall bladder and liver problems, while in Russia and Bulgaria it was used in the treatment of abnormal uterine bleeds and rheumatism.

North American Traditional Uses

In North America, the Eclectics used barberry to treat malaria and as a general tonic. The American Indians found it useful in improving appetite and used the dried fruit as a gargle. Salishan tribe native elders of the Pacific Northwest used Mahonia aquifolium (closely related) to treat acne, and Native Americans utilized Mahonia berries to treat scurvy.

Traditional Preparations

The sundried fruits are eaten for antipyretic and diuretic effects in Turkey. A decoction of the plant has been used to treat gastrointestinal ailments and coughs. The edible fruits have been used to prepare jams, jellies, and juices. The use of the plant in traditional medicine has sometimes been limited by the bitter taste of the bark and root.

4. Key Constituents: Established Mechanisms of Action

AMPK Activation and Metabolic Regulation

The antidiabetic activity of berberine has been attributed to its pleiotropic mechanisms involving activation of AMP-activated protein kinase (AMPK), inhibition of mitogen-activated protein kinases (MAPK), inhibition of the PI3K/Akt signaling pathway, inhibition of aldose reductase, inhibition of inflammation, inhibition of oxidative stress, and modulation of lipid metabolism.

Berberine consistently activates AMPK across various preclinical studies. The activation of AMPK is frequently mediated by pathways involving LKB1 and CAMKKβ. Berberine's activation of AMPK positively impacts glucose uptake, insulin sensitivity, lipid metabolism, oxidative stress, and inflammatory responses.

Berberine can provide cardioprotection in ischemic conditions by modulating AMPK activity, AKT (protein kinase B) phosphorylation, modulation of the JAK/STAT pathway, and GSK3β. AMPK is an important enzyme that plays an essential role in cellular metabolism and offers protection in ischemic conditions by adjusting carbohydrate and lipid metabolism, the function of cell organelles, and apoptosis.

Antioxidant and Anti-Inflammatory Mechanisms

Berberine demonstrates multiple pharmacological actions, including the enhancement of antioxidant enzyme activity, direct scavenging of free radicals, and anti-inflammatory effects. Its antioxidant and anti-inflammatory effects include the activation of endogenous antioxidant enzymes (SOD, CAT, GPx), stimulation of the AMPK, PI3K/AKT, and Nrf2 pathways, alleviation of oxidative stress, inhibition of NADPH oxidase, and reduction of reactive oxygen species (ROS).

Antimicrobial Mechanisms

Berberine can exert an antimicrobial effect by regulating host immunity and also has a significant direct antimicrobial effect. It exhibits various pharmacological activities, including prominent anti-inflammatory and anti-infective effects, antagonizing a variety of pathogenic bacteria (including S. aureus), fungi, parasites, and even viruses. Berberine and its related constituents (such as oxyacanthine) are antibacterial and have been shown to kill amoebae in test tube studies. Berberine inhibits bacteria from attaching to human cells, which helps prevent infection. This compound treats diarrhea caused by bacteria such as E. coli. Berberine also stimulates some immune system cells to function better.

Berbamine: Calcium Channel Blockade

The main effect of berbamine is blocking calcium channels. This alkaloid showed peroxidation activities in experiments on lipid peroxidation of red blood cells and could exert anti-myocardial ischemia and anti-arrhythmia effects.

Cardiovascular Mechanisms

Experiments have shown berberine to exhibit effects on the cardiovascular system, although the mechanisms remain poorly understood. Positive inotropic and negative chronotropic effects, as well as vasodilatory, antiarrhythmic, and hypotensive effects, have been described. Berberine inhibits TRPV4 and MyD88-TLR4 signaling pathways, relaxes vascular smooth muscle, protects endothelial cells from damage, increases NO expression to promote vasodilation, and activates AMPK to inhibit endoplasmic reticulum stress in endothelial cells, safeguarding vascular function.

Insulin Signaling Rescue

Contemporary evidence indicates that berberine rescues insulin signaling at its most vulnerable links—IRS-1 integrity, PI3K engagement, and Akt-driven GLUT4 trafficking—while dampening the inflammatory and stress-kinase landscape that erodes these links in the first place.

5. Scientific Evidence by Area of Use

5.1 Glycemic Control and Type 2 Diabetes

This is the most extensively studied clinical application of barberry and its principal alkaloid berberine. Evidence is derived from numerous randomized controlled trials (RCTs) and multiple systematic reviews and meta-analyses.

A pilot RCT was conducted to determine the efficacy and safety of berberine in the treatment of type 2 diabetic patients. In Study A, 36 adults with newly diagnosed type 2 diabetes were randomly assigned to treatment with berberine or metformin (0.5 g t.i.d.) in a 3-month trial. The hypoglycemic effect of berberine was similar to that of metformin. Significant decreases in HbA1c (from 9.5% ± 0.5% to 7.5% ± 0.4%), fasting blood glucose (FBG; from 10.6 ± 0.9 mmol/L to 6.9 ± 0.5 mmol/L), postprandial blood glucose (from 19.8 ± 1.7 to 11.1 ± 0.9 mmol/L), and plasma triglycerides were observed in the berberine group.

A large systematic review and meta-analysis evaluated the glucose-lowering effect of berberine across multiple RCTs. The results showed that berberine could reduce fasting plasma glucose (WMD = −0.82 mmol/L, 95% CI: −0.95 to −0.70), HbA1c (WMD = −0.63%, 95% CI: −0.72 to −0.53), and 2-hour postprandial blood glucose (WMD = −1.16 mmol/L, 95% CI: −1.36 to −0.96), with all results being statistically significant.

Evidence from animal models demonstrated berberine's efficacy in ameliorating complications such as diabetic nephropathy, neuropathy, retinopathy, cardiomyopathy, hepatic steatosis, bone diseases, atherosclerosis, cognitive dysfunction, and lung injury. Clinical trials reported significant reductions in fasting blood glucose, HbA1c, and lipid levels, with minimal side effects, at standard doses.

Lipid-lowering and insulin-resistance-improving actions are the most studied properties of berberine in numerous randomized clinical trials. However, a limitation across much of this evidence base is that many trials have been conducted in China with relatively small sample sizes, and methodological quality varies. Results are generally consistent in direction but require confirmation from larger, independently conducted, multi-center trials.

5.2 Lipid Profile and Hyperlipidemia

A key systematic review and meta-analysis specifically examined whole barberry (not isolated berberine) on lipid parameters. A meta-analysis of 5 RCTs with 339 participants indicated that barberry supplementation significantly decreased total cholesterol (MD: −23.58 mg/dl, 95% CI: −31.00 to −16.16, P ≤ 0.001), triglyceride (MD: −29.16 mg/dl, 95% CI: −42.91 to −15.41, P ≤ 0.001), and LDL cholesterol (MD: −13.75 mg/dl, 95% CI: −19.31 to −8.20, P ≤ 0.001), whereas changes in HDL cholesterol (MD: 3.40 mg/dl, 95% CI: −0.06 to 6.87, P = 0.054) were not statistically significant. This systematic review and meta-analysis suggested the efficacy of barberry supplementation on lipid parameters; however, further large-scale studies are needed to confirm these results.

Individual clinical trial results have been mixed. In a study by Shidfar et al., daily consumption of 3 g of barberry for 12 weeks in diabetic patients reduced total cholesterol, LDL-C, and TG but had no significant effect on HDL-C. In contrast, Zilaee et al. reported that in patients with metabolic syndrome, 600 mg/day of barberry fruit extract for 6 weeks reduced total cholesterol but had no significant effect on LDL-C or TG concentrations. Ebrahimi et al. reported that in patients with type 2 diabetes, daily consumption of 5 g of barberry fruit with 770 ml of apple cider vinegar for 8 weeks was able to reduce LDL-C and increase HDL-C.

Berberine is considered effective in the prevention of coronary artery diseases and may decrease total cholesterol and triglyceride levels. A meta-analysis concluded that berberine can improve obesity and hyperlipidemia by reducing triglycerides, total cholesterol, and LDL while increasing HDL. Overall, the lipid-modifying evidence for barberry and berberine is considered moderate: consistent in direction across trials but limited by small trial sizes and heterogeneous preparations.

5.3 Cardiovascular Health and Blood Pressure

Barberry is cultivated in Europe and West Asia and its fruit is used in several forms for culinary purposes, jams, and soft drinks. Owing to its berberine and anthocyanin content, effects of this plant have been investigated concerning cardiovascular risk factors in experimental studies. There has been, however, limited clinical trial evidence related to the effect of barberry on cardio-metabolic parameters.

Results from 2 low-quality controlled trials reported significant within-group improvements in diastolic and/or systolic blood pressure with administration of berberine to adults with primary hypertension. One trial showed that 200 ml of barberry juice significantly improved systolic and diastolic blood pressure, fasting blood sugar, and blood lipids in people with type 2 diabetes.

One in vivo study demonstrated that after taking a crude aqueous extract of barberry fruit, measurement of rat arterial blood pressure was significantly reduced, as was heart rate. This is preclinical evidence only. Human clinical evidence for blood pressure specifically remains preliminary and is considered low quality at present.

5.4 Non-Alcoholic Fatty Liver Disease (NAFLD)

Berberine exhibits potential for treating NAFLD, but clinical evidence remains inconclusive. A 2024 meta-analysis and systematic review specifically assessed the efficacy and safety of berberine for NAFLD. Identification of RCTs involved searching 6 databases covering the period from their initiation to September 2023. The primary outcomes comprised liver function markers such as GGT, ALT, and AST, lipid indices, HOMA-IR, and BMI. This meta-analysis demonstrated berberine's efficacy in improving liver enzymes, lipid profile, and insulin sensitivity in NAFLD patients, indicating that berberine shows promise as an adjunct therapy for NAFLD.

The metabolic disorders covered in relevant reviews include non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, impaired glucose tolerance (prediabetes), polycystic ovarian syndrome (PCOS), and hyperlipidemia. These remain active areas of clinical investigation, and current evidence is promising but not yet conclusive.

5.5 Obesity and Body Composition

Berberine can improve obesity and hyperlipidemia by reducing triglycerides, total cholesterol, and LDL, and increasing HDL, in addition to reducing insulin resistance to improve type 2 diabetes. Clinical evidence for barberry specifically in obesity management is more limited than for the isolated alkaloid berberine. Most weight-related evidence derives from studies of isolated berberine rather than whole barberry preparations, and effect sizes are modest.

5.6 Antimicrobial and Gastrointestinal Infections

Although berberine possesses a variety of pharmacological effects including antidiabetic, anti-hyperlipidemic, antimicrobial, anti-inflammatory, and antioxidant activities, berberine has long been used mainly as an agent against gastroenteritis, dysentery, and abdominal pain. Several reports have shown that its anti-gastroenteritic and anti-dysenteric effects are largely attributed to its direct antimicrobial effect on bacterial pathogens.

Berberine exhibits various pharmacological activities including prominent anti-inflammatory and anti-infective effects, antagonizing a variety of pathogenic bacteria (including S. aureus), fungi, parasites, and even viruses. Berberine can exert an antimicrobial effect by regulating host immunity and also has a significant direct antimicrobial effect. Some experimental evidence shows that berberine alone or in combination with other agents showed obvious antimicrobial effects in vivo and in vitro. Berberine even has the potential to inhibit antibiotic-resistant bacteria, which gives it significant relevance in the era of antimicrobial resistance.

Clinical trial evidence specifically on barberry (rather than isolated berberine) for infectious gastrointestinal disease is limited. Much of the antimicrobial evidence remains in vitro or from animal studies, with human evidence being largely historical or observational.

5.7 Anti-Inflammatory and Immunomodulatory Effects

Berberis vulgaris is a well-known herb widely used as a medicinal plant and food additive in Iran. Its anti-inflammatory and immunomodulatory effects have been the subject of systematic investigation. In one study, anti-inflammatory effects of berberine were investigated in non-obese diabetic rats with spontaneously developed type 1 diabetes. The results showed that type 1 diabetes alone causes inflammation in some visceral organs, and the administration of berberine reduced spontaneous thymus and spleen inflammation in mice.

In patients with metabolic syndrome, 600 mg/day of dried barberry for 6 weeks reduced plasma CRP but had no significant effect on LDL-C levels. A 2014 double-blind, randomized, placebo-controlled trial reported that barberry treatment reduces serum anti-heat shock protein 27 and 60 antibody titres and high-sensitivity C-reactive protein in patients with metabolic syndrome. The majority of anti-inflammatory evidence remains preclinical (in vitro and animal studies), with human data being emerging and preliminary.

5.8 Polycystic Ovary Syndrome (PCOS)

In PCOS models, berberine downregulates the TLR4/LYN/NF-κB axis, attenuating ovarian inflammation and cytokine storms. Clinical evidence for barberry or berberine in PCOS is an area of active research but remains limited in sample size and methodological rigor. Multiple studies have suggested beneficial effects of berberine in other metabolic diseases such as cancer, obesity, non-alcoholic fatty liver diseases, hyperlipidemia, and gout.

5.9 In Vitro Anticancer Evidence

Both berberine chloride and barberry ethanolic extract showed inhibitory effects on the growth of breast, liver, and colon cancer cell lines (MCF7, HepG2, and CACO-2, respectively) at different incubation times starting from 24 hours up to 72 hours, and the inhibitory effect increased with time in a dose-dependent manner. Research reveals no clinical data regarding the use of barberry for cancer. Berberine alone has been evaluated as an adjunct to prevent adverse effects of radiation. All anticancer evidence for barberry should be considered in vitro only unless stated otherwise; no clinical evidence of anticancer efficacy currently exists.

5.10 Bacterial Vaginosis

One study compared the efficacy of metronidazole vaginal gel versus Berberis vulgaris combined with metronidazole gel alone in the treatment of bacterial vaginosis (Electronic Physician, 2016). This represents early clinical exploration of barberry in gynecological infections, though confirmatory evidence from larger trials is lacking.

6. Body Systems and Health Areas Associated with Barberry

Traditional use of root, bark, leaf, and fruits of barberry as an immunomodulator and anti-microbial agent, as well as a treatment for central nervous system, cardiovascular, gastrointestinal, endocrine, and renal problems, has been studied in numerous pharmacological investigations.

The principal body systems and health areas associated with barberry and its constituents, based on available evidence, include:

• Endocrine/Metabolic system: Glycemic control, insulin resistance, type 2 diabetes, hyperlipidemia, NAFLD, obesity, PCOS — the most robustly studied area.
• Cardiovascular system: Antiarrhythmic, hypotensive, vasodilatory, cardioprotective effects; evidence is mostly preclinical or from small trials.
• Gastrointestinal system: Anti-diarrheal, antimicrobial, bitter tonic, choleretic; historically the primary application area.
• Immune system: Anti-inflammatory, immunomodulatory; emerging clinical evidence.
• Hepatobiliary system: Support for liver function, bile flow, and NAFLD management.
• Renal/Urinary system: Historically used for bladder and kidney disorders; limited clinical evidence.
• Reproductive system: PCOS, bacterial vaginosis; early-stage clinical investigation.
• Nervous system: Sedative effects (traditional Iranian use); neuroprotective potential in preclinical studies.
• Musculoskeletal system: Traditional use for rheumatism; clinical evidence is limited.

7. Dosages Reported in Clinical Studies

The following dosages are reported directly from cited sources and should not be interpreted as recommended or therapeutic doses:

• Isolated berberine: 0.5 g three times daily (t.i.d.) in a 3-month RCT comparing berberine to metformin in newly diagnosed type 2 diabetes.
• Berberine 300 mg three times daily for 2 weeks in a study examining effects on CYP enzymes in healthy volunteers.
• Barberry fruit: 3 g daily for 12 weeks in diabetic patients, which reduced total cholesterol, LDL-C, and TG.
• Barberry fruit extract: 600 mg/day for 6 weeks in patients with metabolic syndrome.
• Dried barberry: 10 g/day for 8 weeks in a randomized controlled clinical trial in subjects with cardiovascular risk factors.
• Barberry juice: 200 ml daily in patients with type 2 diabetes.
• Tincture (1:5 in 60% ethanol): 1–2 ml in water up to 3 times a day (traditional/herbal practice dosage form).

8. Safety Considerations and Drug Interactions

General Tolerability

Berberine has very low toxicity in usual doses and reveals clinical benefits without major side effects. Only mild gastrointestinal reactions may occur in some patients. Gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea), dizziness, and fainting have been reported. Effects on the cardiovascular system (e.g., hypotension, decreased heart rate) and decreased respiration may occur with high dosages. The German Commission E reports that lower doses of berberine are well tolerated. Hypersensitivity has been documented.

Pregnancy and Neonatal Safety

Barberry is unsafe to use during pregnancy and breastfeeding. Barberry should also not be used by children under the age of 12. It should be used with caution in pregnancy, neonates, and individuals with G6PD (glucose-6-phosphate dehydrogenase) deficiency. Altogether, B. vulgaris and berberine-containing plants are categorized in pregnancy category C. The basis for the pregnancy contraindication includes concerns about uterotonic effects and potential neonatal hyperbilirubinemia, given berberine's displacement of bilirubin from albumin.

CYP450 Enzyme Inhibition and Drug Interactions

Regarding the crucial role of CYP2D6 and CYP3A4 in metabolizing clinically used drugs, and the inhibitory effects of berberine on these two CYP450 isoforms, the most important drug interaction of berberine is related to its inhibitory effect on CYP2D6 and CYP3A4.

After 2 weeks of berberine (300 mg, t.i.d., orally) administration to healthy male volunteers, a decrease in CYP2D6 activity was observed (as the 0–8 h urinary dextromethorphan/dextrorphan ratio increased ninefold, P<0.01). In addition, the losartan/E-3174 ratio doubled (P<0.01), indicating a decrease in CYP2C9 activity.

Consideration should be taken in co-administration of berberine with drugs that are metabolized by CYP enzymes, due to their inhibitory effects on these enzymes.

Cyclosporine Interaction (Clinically Documented)

Berberine is a CYP3A4 inhibitor and a P-glycoprotein transporter substrate. Interaction studies have shown that co-administration markedly elevates the blood concentration of cyclosporine A. The increase in cyclosporine A bioavailability may be partly due to decreased metabolism because of CYP3A4 inhibition. It may be partly due to increased uptake from the gut due to competition for the P-gp transporter. In view of these findings, concomitant use of medicine containing berberine must be avoided during cyclosporine treatment.

The cyclosporine interaction has been demonstrated at doses as low as 300 mg berberine/day in healthy volunteers. Berberine increased plasma accumulation of dextromethorphan, losartan, and midazolam—probe drugs for CYP2D6, CYP2C9, and CYP3A4, respectively.

P-Glycoprotein Inhibition

Case reports are lacking; however, barberry exhibits anti-cytochrome P450 3A4 (CYP3A4) activity similar to that of grapefruit. Beyond CYP450, berberine is also a known inhibitor of P-glycoprotein (P-gp), a major drug efflux transporter found in the gut, liver, kidneys, and blood-brain barrier. Inhibition of P-gp can increase the absorption and reduce the excretion of drugs that are substrates for P-gp, leading to higher systemic drug concentrations.

Cardiac Arrhythmia Caution

Caution is warranted in the presence of cardiac arrhythmia when using barberry or berberine, given the documented effects on heart rate and cardiac conduction.

Cytotoxicity Considerations

Barberry and berberine evoke cytotoxicity on both normal and cancer cell lines, which is time- and concentration-dependent. This cytotoxicity has been documented in vitro and informs caution regarding prolonged high-dose use, though at standard oral doses clinical toxicity in healthy adults has not been a prominent feature of the human trial literature.

9. Evidence Quality Summary

The scientific evidence base for barberry and berberine is extensive relative to many botanical supplements, but varies substantially by indication:

• Glycemic control (Type 2 diabetes): Multiple RCTs and meta-analyses; evidence is moderate to moderately strong for berberine as an isolated compound. Limitations include predominance of small Chinese trials and use of isolated berberine rather than whole barberry.
• Lipid modification: A meta-analysis of 5 RCTs shows consistent directional effects; evidence is moderate for whole barberry on TC, TG, and LDL. HDL effects are not statistically significant.
• NAFLD: Emerging clinical evidence is preliminary but promising; inconclusive at present.
• Blood pressure/cardiovascular: Evidence is weak; limited to small, low-quality trials.
• Anti-inflammatory: Predominantly preclinical evidence; human data are sparse and early-stage.
• Antimicrobial (clinical): Human evidence is limited; strong in vitro and some animal evidence; traditional use well-documented.
• Anticancer: In vitro only; no clinical evidence.
• PCOS/Hormonal: Preliminary and emerging.

Many clinical trials have been conducted and suggest a wide range of therapeutic applications. The clinical uses of berberine and B. vulgaris in the treatment of different human diseases have been investigated through an extensive search of electronic databases. One major clinical review used 77 clinical studies on human subjects. Across the body of evidence, berberine's oral bioavailability is considered relatively low, which has been noted as a pharmacokinetic limitation in extrapolating experimental doses to therapeutic human doses.

References

• Kamrani Rad SZ, Rameshrad M, Hosseinzadeh H. Toxicology effects of Berberis vulgaris (barberry) and its active constituent, berberine: a review. Iran J Basic Med Sci. 2017;20(5):516–529. PMC5478780
• Imenshahidi M, Hosseinzadeh H. Berberine and barberry (Berberis vulgaris): A clinical review. Phytother Res. 2019;33(3):504–523. PubMed 30637820
• Ye Y, et al. Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front Pharmacol. 2021;12:653887. PMC8107691
• Wang H, et al. The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Oxid Med Cell Longev. 2021. PMC8696197
• Ye Y, et al. Application of Berberine on Treating Type 2 Diabetes Mellitus. Int J Endocrinol. 2015. PMC4377488
• Yin J, Xing H, Ye J. Efficacy of Berberine in Patients with Type 2 Diabetes. Metabolism. 2008;57(5):712–717. PMC2410097
• Liang Y, et al. Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis. PubMed 36467075
• Hadi A, Arab A, Ghaedi E, et al. Barberry (Berberis vulgaris L.) is a safe approach for management of lipid parameters: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2019;43:117–124. PubMed 30935518
• Emamat H, et al. The effect of barberry (Berberis integerrima) on lipid profile and systemic inflammation in subjects with cardiovascular risk factors: a randomized controlled trial. BMC Complement Med Ther. 2022;22(1):59. PMC8902769
• Ghasemi Fard M, et al. Effect of barberry (Berberis vulgaris) consumption on blood pressure, plasma lipids, and inflammation in patients with hypertension: study protocol for a randomized clinical trial. PMC7694417
• Kalmarzi RN, et al. Anti-Inflammatory and Immunomodulatory Effects of Barberry (Berberis vulgaris) and Its Main Compounds. Oxid Med Cell Longev. 2019;2019:6183965. PMC6885761
• Zarei A, et al. A quick overview on some aspects of endocrinological and therapeutic effects of Berberis vulgaris L. Avicenna J Phytomed. 2015;5(6):485–497. PMC4678494
• Berberis vulgaris: specifications and traditional uses. PMC5478785
• Neag MA, et al. Berberine: Botanical Occurrence, Traditional Uses, Extraction Methods, and Relevance in Cardiovascular, Metabolic, Hepatic, and Renal Disorders. Front Pharmacol. 2018;9:557. PMC6111450
• Singh S, et al. Addressing the preventive and therapeutic perspective of berberine against diabetes. Biomed Pharmacother. 2024. PMC10663750
• Gao X, et al. The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review. J Transl Med. 2024. PMC10908013
• Pharmacological properties and therapeutic potential of berberine: a comprehensive review. Front Pharmacol. 2025. PMC12391081
• Guo Y, et al. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012. PMC4898966
• Colombo D, Lunardon L, Bellia G. Cyclosporine and Herbal Supplement Interactions. J Toxicol. 2014;2014:145325. PMC3913293
• Abd El-Wahab AE, et al. In vitro biological assessment of Berberis vulgaris and its active constituent, berberine: antioxidants, anti-acetylcholinesterase, anti-diabetic and anticancer effects. BMC Complement Altern Med. 2013;13:218. PMC4016550
• Wang L, et al. A New Perspective on the Antimicrobial Mechanism of Berberine Hydrochloride Against Staphylococcus aureus Revealed by Untargeted Metabolomic Studies. Front Microbiol. 2022. PMC9328669
• Berberis vulgaris Medicinal Plant Monograph. Southern Cross University Analytical Research Laboratory.
• Barberry (Berberis vulgaris): Benefits, Uses, Safety. Herbal Reality.
• Barberry Uses, Benefits & Dosage. Drugs.com Natural Products Database.
• Barberry (Berberis vulgaris): Exploring its nutritional composition, bioactive components, and health benefits for humans. ScienceDirect. 2025.
• Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence. PMC12160363
• Preclinical Evidence of Berberine on Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Animal Studies. PMC8458904